Susquehanna International Group’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.71M Buy
80,001
+28,535
+55% +$1.65M ﹤0.01% 3738
2025
Q4
$2.12M Buy
51,466
+39,405
+327% +$1.53M ﹤0.01% 5543
2025
Q3
$475K Sell
12,061
-18,006
-60% -$460K ﹤0.01% 9081
2025
Q2
$560K Sell
30,067
-17,311
-37% -$325K ﹤0.01% 8903
2025
Q1
$859K Buy
47,378
+30,856
+187% +$680K ﹤0.01% 7637
2024
Q4
$360K Buy
+16,522
New +$425K ﹤0.01% 9418
2024
Q2
Sell
-205,487
Closed -$6.16M 12248
2024
Q1
$6.16M Buy
205,487
+176,808
+617% +$3.84M ﹤0.01% 3301
2023
Q4
$298K Buy
+28,679
New +$317K ﹤0.01% 9856
2023
Q3
Sell
-6,456
Closed -$78.3K 12183
2023
Q2
$78.3K Sell
6,456
-4,888
-43% -$55.6K ﹤0.01% 11115
2023
Q1
$144K Buy
+11,344
New +$126K ﹤0.01% 10950
2022
Q3
Sell
-2,873
Closed -$55K 13343
2022
Q2
$55K Buy
+2,873
New +$71K ﹤0.01% 11926
2022
Q1
Sell
-652
Closed -$46K 13155
2021
Q4
$46K Buy
+652
New +$65.5K ﹤0.01% 12586
2021
Q3
Sell
-1,288
Closed -$201K 12871
2021
Q2
$201K Sell
1,288
-397
-24% -$72.9K ﹤0.01% 11589
2021
Q1
$319K Buy
1,685
+775
+85% +$130K ﹤0.01% 10479
2020
Q4
$114K Sell
910
-289
-24% -$32.8K ﹤0.01% 10432
2020
Q3
$130K Buy
+1,199
New +$142K ﹤0.01% 9780
2019
Q4
Sell
-664
Closed -$109K 9863
2019
Q3
$109K Buy
+664
New +$126K ﹤0.01% 9521

Other funds holding DNTH

Susquehanna International Group's DNTH Position: Q1 2026 in Review

Susquehanna International Group increased its Dianthus Therapeutics (DNTH) stake by 55% in Q1 2026, buying an estimated $1.65M and bringing the position to 80,001 shares worth $6.71M. The position accounts for ﹤0.01% of the portfolio, ranked #3738.

Susquehanna International Group first reported a position in DNTH in Q3 2019 and has held it in 17 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Susquehanna International Group held 80,001 shares of Dianthus Therapeutics worth $6.71M as of Q1 2026.
  • Susquehanna International Group bought 28,535 Dianthus Therapeutics shares in Q1 2026, an estimated $1.65M.
  • Dianthus Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3738 holding.
  • Susquehanna International Group first reported a position in Dianthus Therapeutics in Q3 2019 and has held it in 17 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.